Multimodality therapy offers a chance for cure in patients with pancreatic adenocarcinoma deemed unresectable at first operative exploration
about
Evaluation of gemcitabine efficacy after the FOLFIRINOX regimen in patients with advanced pancreatic adenocarcinoma.Neoadjuvant therapy prior to surgical resection for previously explored pancreatic cancer patients is associated with improved survivalHealth Insurance Expansion and Treatment of Pancreatic Cancer: Does Increased Access Lead to Improved Care?Neoadjuvant Therapy in Clinical Stage II Pancreatic Adenocarcinoma.Overuse of surgery in patients with pancreatic cancer. A nationwide analysis in ItalyComputed tomography-based diagnostics might be insufficient in the determination of pancreatic cancer unresectabilityImportance of b value in diffusion weighted imaging for the diagnosis of pancreatic cancer.Outcomes with FOLFIRINOX for borderline resectable and locally unresectable pancreatic cancer.Phase II Trial of Cetuximab and Conformal Radiotherapy Only in Locally Advanced Pancreatic Cancer with Concurrent Tissue Sampling Feasibility Study.Multiagent induction chemotherapy followed by chemoradiation is associated with improved survival in locally advanced pancreatic cancer.Importance of resectability status in neoadjuvant treatment for pancreatic cancer.Optimal indication of neoadjuvant chemoradiotherapy for pancreatic cancer.Stereotactic ablative radiotherapy (SABR) as primary, adjuvant, consolidation and re-treatment option in pancreatic cancer: scope for dose escalation and lessons for toxicity
P2860
Q33606097-84B05F42-890D-4A4D-AE52-9CFE8EB46735Q33809495-919D1402-70CC-406C-A44E-333CD5B53342Q36327297-66E12624-A051-4714-9AD7-2370962B285AQ36347277-79641013-923E-401F-8B81-C4AB5EDC12E4Q36870686-3BF2CEC4-FD66-42DF-9728-E8E260BC03BCQ36876409-7ACD2137-2055-44F0-A5B5-C7D6B5DB53A1Q37241624-3AEB9176-41A9-42DE-89B8-779998D2BC15Q37277436-6239FD8B-9FA1-45F3-9150-59D1C7F0FB34Q37721562-FFEE3073-012A-46B7-938D-19A178B98D4CQ38722475-78FA5686-E2E4-4767-987A-2A2BE872A044Q41002447-98CD5DB4-5FED-4FB6-A839-ADA067C804D3Q50558607-FF7F7B36-0D4D-4522-A0C4-9193A5002356Q57811272-3AF495FC-9F32-4E8F-98A4-A4206952F8EC
P2860
Multimodality therapy offers a chance for cure in patients with pancreatic adenocarcinoma deemed unresectable at first operative exploration
description
2012 nî lūn-bûn
@nan
2012 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Multimodality therapy offers a ...... at first operative exploration
@ast
Multimodality therapy offers a ...... at first operative exploration
@en
type
label
Multimodality therapy offers a ...... at first operative exploration
@ast
Multimodality therapy offers a ...... at first operative exploration
@en
prefLabel
Multimodality therapy offers a ...... at first operative exploration
@ast
Multimodality therapy offers a ...... at first operative exploration
@en
P2093
P2860
P1476
Multimodality therapy offers a ...... at first operative exploration
@en
P2093
Christopher Crane
Gaury R Varadhachary
James L Abbruzzese
Jason B Fleming
Jeffrey E Lee
Mark J Truty
Matthew H Katz
Robert A Wolff
Ryan M Thomas
P2860
P304
41-51; discussion 51-2
P356
10.1016/J.JAMCOLLSURG.2012.03.024
P577
2012-05-18T00:00:00Z